Renal health and the environment: Heavy metal nephrotoxicity;Medio ambiente y riñón: Nefrotoxicidad por metales pesados

Nefrologia

Volumn 32, Issue 3, 2012, Pages 279-286

  Sabath, Ernesto ^a   Robles Osorio, M Ludivina ^b  

^a Hospital General de Querétaro   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE QUERÉTARO   (Mexico)

Author keywords

Arsenic; Cadmium; Lead

Indexed keywords

ARSENIC; CADMIUM; CARRIER PROTEIN; HEAVY METAL; LEAD;

BODY BURDEN; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DRUG EFFECT; ENVIRONMENTAL EXPOSURE; FOOD CONTAMINATION; HUMAN; INDUSTRIAL WASTE; INTESTINE ABSORPTION; KIDNEY; KIDNEY DISEASE; LEAD POISONING; METABOLISM; NEOPLASM; OCCUPATIONAL DISEASE; PATHOPHYSIOLOGY; POLLUTANT; REVIEW; TRANSPORT AT THE CELLULAR LEVEL;

ARSENIC; BIOLOGICAL TRANSPORT; BODY BURDEN; CADMIUM; CARRIER PROTEINS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; FOOD CONTAMINATION; HUMANS; INDUSTRIAL WASTE; INTESTINAL ABSORPTION; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; LEAD; LEAD POISONING; METALS, HEAVY; NEOPLASMS; OCCUPATIONAL DISEASES;

EID: 84864499801     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Jan.10928     Document Type: Review

References (52)

1. Edwards JR, Prozialeck. Cadmium, diabetes and chronic kidney disease. Toxicol Appl Pharmacol 2009;238:289-93.
2. Garrick MD, Dolan KG, Horbinsky C, Ghio AJ, Higgins D, Porubcin M, et al. DMT1: A mammalian transporter for multiple metals. Biometals 2003;16:41-54.
3. Bradmann A, Eskenazi B, Sutton P. Iron deficiency associated with higher blood lead in children living in contaminated environments. Environ Health Perspect 2001;109:1079-84.
4. Bannon DI, Abounader R, Lees PS, Bressler JP. Effect of DMT1 knockdown on iron, cadmium, and lead uptake in Caco-2 cells. Am J Physiol Cell Physiol 2003;284:C44-50.
5. Sabolic I, Breljak D, Karica MS, Herak-Kramberger. Role of metallothionein in cadmium traffic and toxicity in kidneys and other mammalian organs. Biometals 2010;23:897-926.
6. Liu Y, Liu J, Klaassen CD. Metallothionein-null and wild-type mice show similar cadmium absorption and tissue distribution following oral cadmium administration. Toxicol Appl Pharmacol 2001;175:253-9.
7. Tucker P. Agency for toxic substances and disease registry (ATSDR). Case studies in environmental medicine: cadmium toxicity 2008:10- Available at: www.atsdr.cdc.gov/csem/cadmium/ [Accessed: june 25, 2010].
8. Emmerson BT. "Ouch-Ouch" disease: the osteomalacia of cadmium nephropathy. Ann Intern Med 1970;73:854-5.
9. Adams RG, Harrison JF, Scott P. The development of cadmiuminduced proteinuria, impaired renal function, and osteomalacia in alkaline battery workers. Q J Med 1969;38:425-43.
10. Lauwerys RR, Bernard AM, Buchet JP, Roels HA. Assessment of the health impact of environmental exposure to cadmium: contribution of the epidemiologic studies carried out in Belgium. Environ Res 1993;62:200-6.
11. Järup L, Hellström L, Alfvén T, Carlsson MD, Grubb A, Persson B, et al. Low level exposure to cadmium and early kidney damage: the OSCAR study. Occup Environ Med 2000;57:668-72.
12. Noonan C, Sarasua S, Campagna D, Kathman SJ, Lybarger JA, Mueller PW. Effects of exposure to low levels of environmental cadmium on renal biomarkers. Environ Health Perspect 2002;110:151-5.
13. Hellström L, Elinder CG, Dahlberg B, Lundberg M, Järup L, Persson B, et al. Cadmium exposure and end-stage renal disease. Am J Kidney Dis 2001;38:1001-8.
14. Schwartz GG, Yasova DI, Ivanova A. Urinary cadmium, impaired fasting glucose, and diabetes in the NHANES III. Diabetes Care 2003;26:468-470.
15. Menke A, Muntner P, Silbergeld E, Platz E, Guallar E. Cadmium levels in urine and mortality among U.S. adults. Environ Health Perspect 2009;117:190-6.
16. Gallagher CM, Meliker JR. Blood and urine cadmium, blood pressure, and hypertension: A systematic review and mata-analysis. Environ Health Perspect 2010;118:1676-84.
17. Fujishiro H, Okugaki S, Kubota K, Fujiyama T, Himeno S. The role of ZIP8 down-regulation in cadmium-resistant metallothionein-null cells. J Appl Toxicol 2009;29:367-73.
18. Thévenod F. Catch me if you can! Novel aspects of cadmium transport in mammalian cells. Biometals 2010;23:857-75.
19. Klassen RB, Crenshaw K, Kozyraki R, Verroust PJ, Tio L, Atrian S, et al. Megalin mediates renal uptake of heavy metal methallothionein complexes. Am J Physiol Renal Physiol 2004;287:F393-403.
20. Olivi L, Sisk J, Bressler J. Involvement of DMT1 in uptake of Cd in MDCK cells: role of protein kinase C. Am J Physiol Cell Physiol 2001;281:C793-800.
21. Hirano S, Sun X, DeGuzman C, Ransom R, MacLeish K, Smoyer WE, et al. p38 MAPK/HSP25 signaling mediates cadmium-induced contraction of mesangial cells and renal glomeruli. Am J Physiol Renal Physiol 2005;288:F1133-43.
22. Gunawardana CG, Martínez RE, Xiao W, Templeton DM. Cadmium inhibits both intrinsic and extrinsic apoptotic pathways in renal mesangial cells. Am J Physiol Renal Physiol 2006;290:F1074-82.
23. Barbier O, Jacquillet M, Tauc M, Poujeol P, Cougnon M. Acute study of interaction among cadmium, calcium, and zinc transport along the rat nephron in vivo. Am J Physiol Renal Physiol 2004;287:F1067-75.
24. Klaassen CD, Liu J, Diwan BA. Metallothionein protection of cadmium toxicity. Toxicol Appl Pharmacol 2009;238:215-20.
25. Jacquillet G, Barbier O, Rubera I, Tauc M, Borderie A, Namorado MC, et al. Cadmium causes delayed effects on renal function in the offspring of cadmium-contaminated pregnant female rats. Am J Physiol Renal Physiol 2007;293:F1450-60.
26. Prozialeck WC, Vaidya VS, Liu J, Waalkes MP, Edwards JR, Lamar PC, et al. Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity. Kidney Int 2007;72:985-93.
27. Hotz P, Buchet JP, Bernard A, Lison D, Lauwerys R. Renal effects of low-level environmental cadmium exposure: 5-year follow-up of a subcohort from the Cadmibel study. Lancet 1999;354:1508-13.
28. Nordberg G, Chen L, Lei L, Jin T, Nordberg M. Plasma metallothionein antibody, urinary cadmium, and renal dysfunction in a Chinese type 2 diabetic population. Diabetes Care 2006;29:2682-87.
29. Bernard A. Cadmium and its adverse effects on human health. Indian J Med Res 2008;128:557-64.
30. Meyer P, Brown MJ, Falk H. Global approach to reducing lead exposure and poisoning. Mutat Res 2008;659:166-75.
31. Ekong EB, Jaar BG, Weaver VM. Lead-related nephrotoxicity: A review of the epidemiologic evidence. Kidney Int 2006;70:2074-84.
32. Menke A, Muntner P, Batuman V, Sibergeld E, Guallar E. Blood lead below 10μg/dl and mortality among US adults. Circulation 2006;114:1388-94.
33. Muntner P, He J, Vupputuri S, Coresh J, Batuman V. Blood lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int 2003;63:1044-50.
34. Lin JL, Lin-Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 2003;348:277-86.
35. Tan DT, Lin JL, Yen TH, Chen KH, Huang YL. Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases. Nephrol Dial Transplant 2007;22:2924-31.
36. Wang L, Wang H, Hu M, Cao J, Chen D, Liu Z. Oxidative stress and apoptotic changes in primary cultures of rat proximal tubular cells exposed to lead. Arch Toxicol 2009;83:417-27.
37. Chiu TY, Teng HC, Huang PC, Kao FJ, Yang DM. Dominant role of Orai1 with STIM1 on the cytosolic entry and cytotoxicity of lead ions. Toxicol Lett 2009;110:353-62.
38. Handlogten M, Shiraishi N, Awata H, Huang C, Tyler-Miller R. Extracellular Ca2-sensing receptor is a promiscuous divalent cation sensor that responds to lead. Am J Physiol Renal Physiol 2000;279:F1083-91.
39. Bravo Y, Quiroz Y, Ferrebuz A, Vaziri N, Rodríguez-Iturbe B. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol 2007;293:F616-23.
40. Vaziri N. Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol 2008;295:H454-65.
41. Courtois E, Marques M, Barrientos A, Casado S, López-Farré A. Lead-induced downregulation of soluble guanylate cyclase in isolated rat aortic segments mediated by reactive oxygen species and cyclooxygenase-2. J Am Soc Nephrol 2003;14:1464-70.
42. Ni Z, Hou S, Barton C, Vaziri N. Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells. Kidney Int 2004;66:2329-36.
43. Bennett W. Lead Nephropathy. Kidney Int 1985;28:212-20.
44. Lin JL, Yu CC, Lin-Tan D, Ho HH. Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout. Kidney Int 2001;60:266-71.
45. Potula V, Henderson A, Kaye W. Calciotropic hormones, bone turnover, and lead exposure among female smelter workers. Arch Environ Occup Health 2005;60:195-204.
46. Mahmudur-Rahman R, Ng JC, Naidu R. Chronic exposure of arsenic via drinking water and its adverse health impacts on humans. Environ Geochem Health 2009;31:189-200.
47. Hsueh YM, Chung CJ, Shiue HS, Chen JB, Chiang SS, Yang MH, et al. Urinary arsenic species and CKD in a Taiwanese population: A case-control study. Am J Kidney Dis 2009;54:859-70.
48. Meliker JR, Wahl RL, Cameron LL. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: A standardized mortality ratio analysis. Environ Health 2007;6:4-10.
49. Thomas D. Unraveling arsenic-glutathione connections. Toxicol Sci 2009;107:309-11.
50. Carbrey JM, Song L, Zhou Y, Yoshinaga M, Rojek A. Reduced arsenic clearance and increased toxicity in aquaglyceroporin-9-null mice. Proc Natl Acad Sci U S A 2009;106:15956-60.
51. Lee TC, Ho IC, Lu WJ, Huang JD. Enhanced expression of multidrug resistance-associated protein 2 and reduced expression of aquaglyceroporin-3 in an arsenic-resistant human cell line. J Biol Chem 2006;281:18401-7.
52. Huang M, Choiu SJ, Kim DW, Kim NY, Park CH, Yu SD et al. Risk assessment of low-level cadmium and arsenic on the kidney. J Toxicol Environ Health A 2009;72:1493-8.